GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment
Betsy Goodfellow | December 18, 2023 | News story | Research and Development | GSK, Jemperli, Oncology, Zejula, endometrial cancer
GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which assessed Jemperli (dostarlimab) plus standard of care chemotherapy (carboplatin and paclitaxel) followed by Jemperli plus Zejula (niraparib) as a maintenance therapy in adult patients with primary advanced or recurrent endometrial cancer.
The trial met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful improvement observed in the overall patient population as well as in a subpopulation of patient with mismatch repair proficient/microsatellite stable (MMRp/MSS) tumours.
The safety profile of dostarlimab plus carboplatin and paclitaxel, as well as dostarlimab plus niraparib, remained generally consistent with the known profiles of the individual drugs.
Hesham Abdullah, senior vice president and global head Oncology, Research and Development at GSK, commented: “Patients with MMRp/MSS primary advanced or recurrent endometrial cancer have few approved treatment options. Today’s positive topline results reinforce our approach of building combination therapies with dostarlimab as the backbone in an effort to improve patient outcomes and options.”
Full analysis of the trial data, including a secondary endpoint of overall survival (OS), is ongoing, with full results expected to be presented at an upcoming scientific meeting, published in a medical journal and submitted to the relevant regulatory authorities.
Betsy Goodfellow
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …
